Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression

Veronica Henderson, Basil Smith, Liza J Burton, Diandra Randle, Marisha Morris, and Valerie A Odero-Marah*

Center for Cancer Research and Therapeutic Development; Department of Biological Sciences; Clark Atlanta University; Atlanta, GA USA

Keywords: cell migration, MAPK pathway, PI3K/AKT pathway, Rac1, snail

Abbreviations: EMT, epithelial to mesenchymal transition; Rac1, Ras-related C3 botulinum toxin substrate 1; CaP, prostate cancer; PI3K/AKT pathway, Phosphoinositide 3-kinases/Protein Kinase B; ERK, Extracellular signal-regulated kinases; P-ERK, Phospho-ERK; P-AKT, Phospho-AKT.

Snail, a zinc-finger transcription factor, induces epithelial-mesenchymal transition (EMT), which is associated with increased cell migration and metastasis in cancer cells. Rac1 is a small G-protein which upon activation results in formation of lamellipodia, the first protrusions formed by migrating cells. We have previously shown that Snail promotes cell migration through down-regulation of maspin tumor suppressor. We hypothesized that Snail’s regulation of cell migration may also involve Rac1 signaling regulated by PI3K/AKT and/or MAPK pathways. We found that Snail overexpression in LNCaP and 22Rv1 prostate cancer cells increased Rac1 activity associated with increased cell migration, and the Rac1 inhibitor, NSC23766, could inhibit Snail-mediated cell migration. Conversely, Snail downregulation using shRNA in the aggressive C4–2 prostate cancer cells decreased Rac1 activity and cell migration. Moreover, Snail overexpression increased ERK and PI3K/AKT activity in 22Rv1 prostate cancer cells. Treatment of Snail-overexpressing 22Rv1 cells with LY294002, PI3K/AKT inhibitor or U0126, MEK inhibitor, decreased cell migration significantly, but only LY294002 significantly reduced Rac1 activity, suggesting that Snail promotes Rac1 activation via the PI3K/AKT pathway. Furthermore, 22Rv1 cells overexpressing Snail displayed decreased maspin levels, while inhibition of maspin expression in 22Rv1 cells with siRNA, led to increased PI3K/AKT, Rac1 activity and cell migration, without affecting ERK activity, suggesting that maspin is upstream of PI3K/AKT. Overall, we have dissected signaling pathways by which Snail may promote cell migration through MAPK signaling or alternatively through PI3K/AKT-Rac1 signaling that involves Snail inhibition of maspin tumor suppressor. This may contribute to prostate cancer progression.

Introduction

Prostate Cancer (CaP) is the second leading cause of cancer death in males in the United States.1 In 2014, it is estimated that 29, 480 men will die from CaP and that there will be 233,000 new cases in the United States.2 In CaP, as in many other types of cancer, metastasis of the primary tumor is the main cause of cancer related death. About 90% of cancers, including prostate cancer, originate from the epithelial tissue.3 In the initial tumorigenesis stages, the tumor cells alter their properties from highly differentiated epithelial morphology to a migratory and invasive phenotype.3 This phenomenon is referred as epithelial to mesenchymal transition (EMT). It is therefore important to find therapeutics targeted at halting or slowing down prostate cancer metastasis.

Snail is a zinc-finger transcription factor that binds to E-box consensus sequence of their target genes.4 There are 3 family members of Snail; Snail1, Snail2/ Slug, and Snail3.5 We are interested in studying Snail1 or Snail as it is more commonly known. Snail is a master regulator of EMT known to have both repressive and activating effects on gene transcription. For example, it suppresses the transcription of epithelial genes and enhances transcription of mesenchymal genes.4 Snail acts as a regulator of EMT through its role of down-regulating E-cadherin expression, a cell adhesion molecule,6 which leads to loss of cell-cell adhesion and increased cell motility.3,7 Snail has been shown to be up-regulated in prostate cancer resulting in increased cell invasion.7,8

Ras-related C3 botulinum toxin substrate 1 (Rac1) is a member of the Rho subfamily of small guanosine triphosphate
(GTP)-binding proteins. There are 5 family members, Rac1, Rac1b, Rac2, Rac3, and RhoG. Rac proteins are activated by upstream signaling from tyrosine kinase, integrins, and G protein coupled receptors (GPCRs). Small GTPases act as molecular switches in which the GTP-bound form is active and guanosine diphosphate (GDP)-bound form is inactive. Rac1 activation is facilitated by the activity of guanine nucleotide exchange factors (GEFs) such as Tiam1, which allow for the exchange of GDP bound to GTP bound. On the other hand, Rac1 inactivation requires the activity of a GTPases activating proteins (GAPs) such as ArhGAP15, to hydrolyze the GTP to GDP inactive form. When Rac1 is in the GTP-bound, active form, it can interact with its effectors such as Riam (an adaptor that binds to actin regulators) in order to regulate downstream cellular functions. Some of the roles of Rac proteins include, actin reorganization and cell motility through the formation of membrane ruffles and lamellipodia, phagocytosis, endocytosis and cell adhesion. During cell migration, the formation of lamellipodia is important as they are the first protrusions formed by migrating cells as the move forward. Rac1 has been reported to be activated in breast cancer cells leading to increased cell invasion. Therefore, activated Rac1 levels are associated with more aggressive cancers.

The PI3K/AKT pathway is activated via the stimulation of the receptor tyrosine kinase (RTK) by its ligand(s) and phosphorylation of its cytoplasmic tail. This leads to the recruitment of PI3K (p85-p110 complex) to the active RTK receptor and its activation. PI3K then phosphorylates phosphatidylinositol-4,5-bisphosphate (PtdIns (4,5) P2) to produce PtdIns (3,4,5) P3 or PIP3 which then acts as a second messenger that binds to domains of its downstream targets recruiting them to the membrane. Production of PIP3 leads to recruitment of AKT where 3-phosphoinositide- dependent protein kinase-1 (PDK1) phosphorylates AKT. The PI3K/AKT pathway is usually aberrantly expressed in cancers such as ovarian, breast, digestive tract and thyroid. This pathway is known to regulate cell growth, translation, metabolism and proliferation. Activation of PI3K has been shown to activate GEFs for Rac1. Therefore, Rac1 seems to be a downstream target of PI3K signaling pathway.

Maspin (mammary serine protease inhibitor) is a tumor suppressor that is down-regulated in prostate cancer. It is a serine protease inhibitor that has been shown to inhibit Rac1 activity and subsequently PAK activity leading to decreased cell migration in breast cancer cells. Snail transcription factor has been shown to bind to maspin promoter and negatively regulate it in human prostate cancer cells resulting in decreased cell migration and invasion. Mitogen- activated protein kinase/ Extracellular regulated kinases (MAPK/ERK) pathway is activated by various factors such as G-protein coupled receptors (GPCR), Receptor tyrosine kinases (RTK), integrins, and ion channels. It is important during differentiation, cell growth and survival and often aberrantly activated in human cancers. ERK has been shown to play a role during cell migration by suppressing integrins (which are receptors which mediate cell-matrix attachments) from binding to their extracellular matrix ligands thus controlling their activation. The role of the ERK pathway during tumor migration has been reported and shown to involve in part, Rac1.

Snail, PI3K/AKT pathway, and Rac1 have been shown to be aberrantly expressed in human cancers and Rac1 and PI3K/AKT pathway suggested as good therapeutic targets for cancer. One of the mechanisms for Snail regulating tumor progression is through AKT upregulating NF-kB which transcriptionally increases Snail expression and results in more EMT. Recently, Snail has been shown to increase Rac1 activity in regulating cell migration. However, the signaling pathway by which Snail may regulate Rac1 has not been shown. Moreover, the regulation of Rac1 by maspin has also never been shown in CaP. Here we show for the first time that Snail, which is upregulated in prostate cancer, can increase cell migration through MAPK signaling or PI3K/AKT-mediated Rac1 activation through repression of maspin tumor suppressor. We also show that the PI3K/AKT pathway but not the ERK pathway, is involved in Snail-Rac1 mediated cell migration. Put together, we show for the first time that Snail regulates cell migration during CaP through inactivation of maspin tumor suppressor which subsequently allows for recruitment of PI3K/AKT and Rac1 signaling pathways.

Results

Snail overexpression is associated with increased cell migration and Rac1 activity in LNCaP and 22Rv1 prostate cancer cells

Previously we generated LNCaP and 22Rv1 cell lines that overexpress the Snail gene and showed that this increases cell migration. We confirmed these results; as shown by western blotting, LNCaP and 22Rv1 cells transfected stably with Snail display increased expression of Snail protein (Fig. 1A). Furthermore, the 22Rv1 and LNCaP Snail overexpressing cell lines showed increased cell migration compared to the Neo vector control (Fig. 1B). Recently, it has been shown that Snail-induced migration and scattering was mediated by Rac1 small GTPase in pancreatic cancer cells. We hypothesized that similarly, Snail would regulate Rac1 activity in prostate cancer cells. Since Rac1 activity has been shown to control cell migration through formation of lamellipodia, we determined the Rac1-GTP levels in LNCaP and 22Rv1 overexpressing Snail. Our results showed that activated Rac1 levels were increased in the 22Rv1 and in LNCaP cells overexpressing Snail as shown using the G-LISA method (Fig. 1C). Therefore, Snail overexpression results in higher cell migration and Rac1 activity in prostate cancer cells.

Knockdown of Snail results in reduced cell migration and Rac1 activity in the aggressive C4–2 prostate cancer cells

We next used C4–2 with stable knockdown of Snail (C4–2 shRNA) to observe their effect on cell migration and Rac1 activity. We observed that Snail expression was decreased upon Snail knockdown as compared to non-silencing control (Fig. 2A) which was accompanied by decreased cell migration (Fig. 2B).
in C4–2 cells, as previously reported, possibly through Rac1 further proof that the Snail gene is important for cell migration.

In addition, the Rac1 activity was significantly reduced in C4–2 Snail shRNA expressing cells (Fig. 2C). Therefore, we provide further proof that the Snail gene is important for cell migration in C4–2 cells, as previously reported, possibly through Rac1 activation.

Rac1 inhibitor antagonizes Snail-mediated cell migration

NSC23766, a Rac1 inhibitor, has been shown to decrease Rac1 activity. We treated 22Rv1 cells overexpressing Snail with this Rac1 inhibitor for 24 hrs and showed that there was a dose-dependent decrease in Rac1 activity (Fig. 3A). The Rac1 inhibitor at lower concentrations (50–100 μM) did not significantly affect Rac1, Snail, maspin, PI3K/AKT activity (p-AKT) or MAPK activity (p-ERK) (Fig. 3B). Interestingly, the highest dose (200 μM) appeared to decrease Rac1 and Snail protein expression, but did not affect PI3K/AKT, MAPK activities or maspin protein levels (Fig. 3B). We also performed a migration assay following treatment of 22Rv1 Snail cells with Rac1 inhibitor and observed significantly decreased cell migration especially with the 200 μM dose (Fig. 3C). Put together, Rac1 inhibitor antagonizes Snail-mediated cell migration without affecting PI3K/AKT, MAPK activities or maspin protein level. These data but did not change significantly in LNCaP cells overexpressing Snail compared to parental cells or C4–2 cells with Snail knockdown (Fig. 4A). We next tested whether Rac1 activity increased by Snail was mediated via the MAPK pathway by utilizing the MEK inhibitor, U0126. By protein gel blotting, we observed that the p-ERK but not p-AKT levels were diminished within 30 min up to 24 hrs as a result of treating 22Rv1 cells overexpressing Snail with the U0126 inhibitor for various time points as expected (Fig. 4B). In addition, Snail levels decreased briefly by 30 min, then increased after 24 hrs time-point (Fig. 4B). On the other hand, maspin protein levels seemed to increase between 2–2 4 hrs while Rac1 levels were unaffected (Fig. 4B). Overall, it seems that treatment of 22Rv1 overexpressing Snail cells with MEK inhibitor resulted in reduced Snail and increased maspin expression. These results show that the ERK pathway may be involved in the Snail regulation of maspin in 22Rv1 cells. Interestingly, the Rac1 activity levels did not change significantly with MEK inhibitor treatment (Fig. 4C), while cell migration was decreased compared to control (Fig. 4D). Therefore, we concluded that the ERK pathway is not involved in the Snail regulation of Rac1 activity in 22Rv1 cells but it can regulate Snail-mediated cell migration by an alternate pathway.

The ERK pathway regulation of Snail-mediated cell migration does not involve Rac1 activity

Next, we wanted to find out if Snail and Rac1 regulate cell migration through the ERK or the AKT signaling pathway. To test this, we first looked at the basal protein activity for AKT and ERK. LNCaP and C4–2 cells appeared to have constitutively high levels of phospho-AKT (p-AKT) even before overexpression of Snail or after Snail knockdown, which is expected as LNCaP and C4–2 cells have mutated PTEN gene (Fig. 4A). However, Snail overexpression in 22Rv1 cells resulted in greater AKT activity as compared to Neo control (Fig. 4A). Additionally, phospho-ERK (p-ERK) levels increased with overexpression of Snail in 22Rv1 cells.

Figure 1. Snail overexpression increases cell migration and Rac1 activity in prostate cancer cells. (A) LNCaP and 22Rv1 prostate cancer cells stably transfected with empty vector (Neo) or constitutively active Snail cDNA using lipofectamine 2000 were tested by protein gel blot to assess the Snail protein levels. (B) A cell migration assay was done using the LNCaP and 22Rv1 cells overexpressing Snail or Neo control using a boyden chamber. 5 × 10⁴ cells were plated in the upper chamber of inserts coated with collagen I. Cells that migrated through the pores to the underside of the insert were stained with crystal violet, imaged, as well as counted and graphed. (C) Rac1 activity assay was performed using G-LISA Rac1 activity assay followed by analysis at O.D. 590 nm and the values used to calculate the percent Rac1 activation compared to Neo vector control. Actin was utilized as a loading control. Results are representative of 2 independent experiments done in triplicates and western blots done as 3 independent experiments. Statistical significance was assessed using GraphPad Prism software by paired Student’s t-test compared to Neo-transfected control cells (\( ^* P < 0.05, ^{**} P < 0.01, ^{***} P < 0.001 \)).
The PI3K/AKT pathway regulates the Snail- Rac1 mediated cell migration
LY294002 has been shown to inhibit the PI3K/AKT signaling pathway.42 We wanted to determine if the Snail regulation of Rac1 activity and cell migration is through PI3K/AKT signaling. We therefore treated 22Rv1 Snail-overexpressing cells with LY294002 inhibitor for various time-points, followed by western blotting, Rac1 activity assay and migration assay. Following treatment with LY294002, as expected, p-AKT decreased within 30 min while p-ERK levels did not decrease (Fig. 5A). Snail expression decreased within 30 min but returned by 24 hrs (Fig. 5A). On the other hand, the maspin protein levels seemed to increase slightly by 4 hrs up to 24 hrs while Rac1 levels did not significantly change (Fig. 5A). In addition, Rac1 activity decreased significantly within 30 minutes, up to 24 hrs (Fig. 5B). Concomitantly, the cell migration decreased significantly after the 24 hrs (Fig. 5C). Therefore, the PI3K/AKT signaling pathway is involved in the Snail- Rac1 mediated cell migration and may act upstream of Rac1 as we saw a decrease in Rac1 activity after treatment of 22Rv1 Snail-overexpressing cells with the PI3K/AKT inhibitor.

Maspin suppresses Rac1 activity via inhibition of PI3K/AKT activity
Since Snail is known to transcriptionally downregulate maspin26 and maspin has been previously shown to repress Rac1 activity in breast cancer cells,25 we wanted to see whether maspin could be a possible link between Snail and Rac1 activity. To do this, we first confirmed that Snail overexpression in 22Rv1 cells leads to downregulation of maspin as compared to Neo control cells (Fig. 6A). Subsequently, we transiently knocked down maspin in 22Rv1 Neo cells with maspin siRNA then tested for maspin and PI3K/AKT activity by protein gel blot analysis. Interestingly, when we knocked down maspin, p-AKT increased while p-ERK was not affected (Fig. 6B). In addition, we performed a Rac1 activity assay to assess if the levels of activated Rac1 changed after treatment with the maspin siRNA. We observed that Rac1 activity increased following maspin knockdown, \( P = 0.068 \) (Fig. 6C). This observation is indicative of the normal role of maspin as repressing Rac1 activity hence when maspin is knocked down, the Rac1 activity levels increased. We also did a migration assay after knocking down maspin in 22Rv1 Neo cells and observed a significant increase in cell migration (Fig. 6D). Therefore, Snail may lead to suppression of maspin which results in activation of AKT and Rac1 leading to increased cell migration in 22Rv1 prostate cancer cells.

Discussion
Tumor metastasis is a complex process that involves increased cell motility, recruitment of cellular components such as matrix metalloproteases to degrade the extracellular matrix, cell proliferation, among other features.43 One of the early steps during the metastatic process is EMT, during which epithelial cells lose their adhesions to neighboring cells and acquire migratory capabilities.44 Snail is known to regulate EMT through its role in downregulating E-cadherins.6 To further elucidate the
The role of Snail during CaP progression, we overexpressed Snail in androgen-dependent, LNCaP and 22Rv1 cell lines. We have previously shown that Snail overexpression in prostate cancer cells induces EMT associated with increased migration, invasion and tumorigenicity. We have also shown previously that Snail may promote cell migration and invasion through repression of maspin tumor suppressor by binding to E-boxes located in the promoter region. Rac1 activity is involved in cell migration and maspin has been shown to repress Rac1 activity in breast cancer cells. Rac1 activity is involved in cell migration and maspin has been shown to repress Rac1 activity in breast cancer cells. Moreover, Snail has been shown to promote cell migration and scattering in pancreatic cancer cells by activation of Rac1 although the signaling mechanism was not delineated. Therefore, we hypothesized that Snail may regulate Rac1 activity and cell migration in prostate cancer cells via PI3K/AKT and/or MAPK signaling pathway, which has never been reported. We found that Snail-overexpressing LNCaP and 22Rv1 cells displayed increased migration and Rac1 activity. Next, utilizing C4–2 cells with stable knockdown of Snail, we observed that these cells had decreased cell migration, as previously reported, and reduced Rac1 activity. This supports the conclusion that Snail may mediate cell migration partly through increased Rac1 activity in prostate cancer cells. We further observed that NSC23766, a Rac1 inhibitor, could significantly decrease Snail-mediated cell migration at a dose of 100–200 μM. Interestingly, treatment with the Rac1 inhibitor reduced Snail protein levels which suggests that although Snail can increase Rac1 activity, this may further aid in maintaining Snail protein levels by a positive feedback loop. Indeed, expression of Rac1b, a splice variant of Rac1, in SCp2 mouse mammary epithelial cells has been shown to increase reactive oxygen species which led to increased expression of Snail and EMT.

Although MAPK pathway has been implicated in cell migration and has been found to regulate Rac1, our data suggested that Snail-mediated Rac1 activation in 22Rv1 cells is not mediated by MAPK pathway, as the MEK inhibitor did not affect Rac1 activity. However, the MEK inhibitor still resulted in decreased cell migration, suggesting that the MAPK pathway can utilize Rac1-independent pathways to regulate cell migration. Indeed, it has been shown that ERK-dependent Fra-1 activation promotes cell motility by inactivation β-1 integrin levels and decreasing RhoA activity.

PI3K/AKT has been reported to be activated during EMT through the regulation of E-cadherin and Rac1 has been shown to be a downstream target of this pathway. We found that LY294002, a PI3K/AKT inhibitor, led to a decline in both Snail-mediated Rac1 activity and cell migration. This supports the conclusion that Rac1 is downstream of the PI3K/AKT pathway and that this pathway cooperates with Snail and Rac1 to mediate cell migration during tumor progression. We noted that although Snail decreased only transiently following inhibitor treatments, maspin increase was more sustained and migration occurred later after 24 hrs. We believe that Snail is an immediate early gene that may exert its effect transiently, especially when treated with the inhibitors. Its expression decreases...
only transiently, but enough to affect other effector genes such as maspin that then increase but stay on longer and may then exert effects such as decreased cell migration at later time points such as 24 h, when by then Snail has already recovered.

We speculated on a mechanism by which Snail would be able to increase Rac1 activity. Since we had recently published that Snail can decrease the promoter activity of maspin tumor suppressor resulting in decreased maspin protein expression and cell migration,26 and previous studies had shown that maspin can repress Rac1 activity,25 it seemed logical to test whether maspin could be a link between Snail and Rac1. We did indeed confirm that maspin was repressed by Snail and that alternatively if we inhibited maspin expression with siRNA in maspin expressing 22Rv1 Neo cells, then this resulted in higher Rac1 protein levels. Western blot data for Snail and maspin was quantified using Image J Software from NIH. 

Collectively, our data supports a pathway in which Snail can promote cell migration via multiple pathways in prostate cancer cells; Snail activation of MAPK pathway can promote cell migration, while Snail repression of maspin tumor suppressor can lead to PI3K/AKT activation resulting in Rac1 activation (Fig. 7). Interestingly, inhibition of MAPK or PI3K/AKT pathway decreased Snail levels suggesting a positive feedback loop may exist from these pathways to maintain Snail levels; however, the mechanism of how this would occur remains unclear. In summary, our study shows that Snail-mediated cell migration acts in part via MAPK signaling and in part via maspin suppression and PI3K/AKT- Rac1 activation during CaP progression.

Materials and Methods

Reagents and antibodies
RPMI medium was purchased from Lonza, Waltersville, MD and penicillin/streptomycin was purchased from Cell Gro, Manassas, VA. Rat tail collagen type I used for migration

Figure 4. Snail-Rac1 signaling is not regulated by the ERK pathway in 22Rv1 cells. (A) Western blot analysis was performed using LNCaP and 22Rv1 Neo and Snail over-expressing cells or C4–2 cells with stable Snail knockdown, to assess the levels of total and phospho-AKT (p-AKT) and total and phospho-ERK (p-ERK). (B) 22Rv1 Snail-overexpressing cells were treated with 20 μM U0126, MEK inhibitor, for various time points and a western blot analysis performed to measure the total and p-ERK and AKT levels, Snail, maspin and Rac1 protein levels. Western blot data for Snail and maspin was quantified using Image J Software from NIH. (C) Rac1 activity assay was performed following treatment of 22Rv1 Snail-overexpressing cells with U0126, using the G-LISA Rac1 activity assay. (D) A migration assay was also performed after 24 hrs treatment of 22Rv1 Snail-overexpressing cells with the U0126. Actin was used as a loading control. Results are reported as mean ± SD from 3 independent experiments. Statistical significance was assessed using GraphPad Prism software by paired Student’s t-test compared to 22Rv1 Snail control cells treated with DMSO (**P < 0.01, ***P < 0.001).
The assay was obtained from BD Biosciences, Bedford, MA. The protease inhibitor cocktail was from Roche Molecular Biochemicals, Indianapolis, IN. Mouse monoclonal anti-human maspin antibody was from BD Transduction Laboratories, Lexington, KY. G418 and anti-human actin antibodies were from Sigma-Aldrich, Inc., St Louis, MO. Rabbit monoclonal anti-human Snail antibody, Rabbit monoclonal anti-human phospho-AKT, phospho-ERK antibodies and HRP-conjugated goat anti-rat antibody were from Cell Signaling Technology, Inc., Danvers, MA. HRP-conjugated sheep anti-mouse antibody and HRP-conjugated donkey anti-rabbit were purchased from Amersham Biosciences, Buckingham, England. Enhanced chemiluminescence (ECL) prime western blotting detection reagent was purchased from Thermo Fisher Scientific Inc., Waltham, MA. Fetal bovine serum (FBS) was from PAA laboratories Inc., Dartmouth, MA. Charcoal/dextran treated FBS (DCC-FBS) was from HyClone, South Logan, UT. Rac1 antibody and Rac1 activation assay kit was purchased from Upstate (Millipore), Billerica, MA. The G-LISA Rac1 Activation Assay Biochem Kit (Absorbance Based) was purchased from Cytoskeleton, Inc., Denver, CO. PI3K/AKT inhibitor (LY294002) and Rac1 inhibitor (NSC23766) were purchased from EMD Millipore, Billerica, MA. MEK inhibitor (U0126) was purchased from Sigma-Aldrich corp., St. Louis, MO, USA.

**Cell culture**

The human prostate cancer cell lines, LNCaP, and 22Rv1 were obtained from ATCC, Manassas, VA. LNCaP and 22Rv1 cells stably overexpressing Snail utilized in these experiments were previously generated. C4–2 cells were a kind gift from Dr. Leland Chung (Cedar Sinai Medical Center, Los Angeles, CA). C4–2 cells with stable knockdown of Snail using shRNA were previously generated. Cells were grown in RPMI medium supplemented with 10% fetal bovine serum and 1× penicillin-streptomycin (plus 400 μg/ml G418 for Snail overexpressing cells), at 37°C with 5% CO2 in a humidified incubator.

**Western blot analysis**

Confluent cells were lysed in a modified RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.02% NaN3, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate) containing 1.5× protease inhibitor cocktail, 1 mM phenylmethylsulfonyl fluoride, and 1 mM sodium orthovanadate. The cell lysates were centrifuged, and supernatants collected and quantified using a micro BCA assay. 30–50 μg of cell lysate was resolved on a 10–13% SDS PAGE, followed by transblotting onto nitrocellulose membrane from Schleicher & Schuell, Keene, NH. The membranes were blocked in TBS-T (Tris Buffer Saline with 0.05% Tween-20) containing 3% milk, and subsequently incubated with diluted antibody in blocking buffer. After washing, the membranes were incubated in peroxidase-conjugated sheep anti-mouse, donkey anti-rabbit, or goat anti-rat IgG, then washed, and visualized using ECL prime reagent. The membranes were stripped using stripping buffer (Pierce Biotechnology, Inc., Rockford, IL) prior to re-probing with a different antibody.

**siRNA Transfection**

22Rv1 Neo cells (5 × 10⁵ cells per well) were plated in 6-well plates in growth media and left overnight for attachment. The next day, maspin siRNA (Human SERPINB5, Dharmacon, Inc.) transfections were performed according to the manufacturer's instructions.
to manufacturer instructions. The maspin siRNA were pooled from 4 On-Target plus SMARTpool siRNA with the following identities and target sequences: J-019684-08, target sequence: GAAGAAAUUUCCUGAAUCA, J-019684-07, target sequence: AAUCUAGGGCUGAAACAUA, J-019684-06, target sequence: CGAAAGGUCAGAUCAACAA, J-019684-05, target sequence: UGGGAAACAUUGACAGUAU.

Briefly, the growth media was removed from cells and the cells washed with sterile Phosphate Buffered saline (1× PBS). Control and maspin siRNA transfection reagents were prepared in phenol and serum-free RPMI at a concentration of 200 nM, and then added to their corresponding wells in the 6-well plates. For the untreated control cells, only media was added to wells. The cells were incubated at 37°C, 5% CO2 for 5 hours after which the media was replaced with 2 ml of phenol-free charcoal stripped media (5% DCC) followed by incubation at 37°C, 5% CO2 for 72 hours. Cell lysates were then harvested after the given time period.

**Inhibitor treatment**

22Rv1 Snail-transfected cells were plated at 1.25 × 10^6 cells in T-75 flasks and treated with 20 μM LY294002 or U0126 inhibitors for time points, 30 min, 2 hrs, 4 hrs, 24 hrs, 72 hrs and controls were treated with DMSO. Treatment with NSC23766 at 50 μM, 100 μM and 200 μM was performed for 24 hrs, using double distilled water as a control. All treatments were performed using RPMI phenol-free supplemented with 5% DCC-FBS.

**In vitro cell migration assay**

We utilized Costar 24-well plates containing a polycarbonate filter insert (BD Biosciences, Franklin Lakes, NJ) with an 8-μm pore size, coated with rat tail collagen I on the outside for migration assays. 50,000 cells were plated in the upper chamber containing 0.1% fetal bovine serum (FBS) while the lower chamber contained 10% FBS. 24 hrs later, cells that had migrated to the bottom of the insert was fixed with 10% formalin, stained with crystal violet, and counted to obtain the relative cell migration.

**Rac1 activity assay**

Cells were allowed to grow to 70–80% confluency before the protein lysates were collected. In order to analyze Rac1 activity...
we utilized a Rac1 G-LISA kit. The Rac1 G-LISA kit has a Rac1 binding property. FEBS Lett 2003; 539:131-7; PMID:12650940; http://dx.doi.org/10.1016/S0014-5793(03)00213-8

13. Adhiri M, Venkatesan N, Kadamal M, Bhow J, Krishnakumar S. Expressions of Rac1, Tiam1 and Cdc42 in retinoblastoma. Exp Eye Res 2006; 83:1446-52; PMID:17027002; http://dx.doi.org/10.1016/j.exer.2006.08.003

14. Seoh ML, Ng CH, Yong J, Lim L, Leung T, Arghapati5, a novel human RacGAP protein with GTPase binding property. FEBS Lett 2003; 539:131-7; PMID:12650940; http://dx.doi.org/10.1016/S0014-5793(03)00213-8

15. Lafuente EM, van Puijenbroek AA, Krause M, Carman CV, Freeman CJ, Berezovkaya A, Constantine E, Springer TA, Gertler FB, Bossiati VI, RA, Roan E, Glasser J, Inglis JD, Orrell J. Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells. Breast Cancer Res Treat 2005; 7: R965-74; PMID:16280046; http://dx.doi.org/10.1007/s10549-005-8132-0

16. Baugher PJ, Krishnamoorthy L, Price JE, Dharmathri S, Fedorowicz SF. Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells. Breast Cancer Res Treat 2005; 7: R965-74; PMID:16280046; http://dx.doi.org/10.1007/s10549-005-8132-0

17. Wells CM, Walsmey M, Osu S, Tybulewicz V, Ridley AJ. Rac-deficient macrophages exhibit defects in cell spreading and membrane ruffling not migration. J Cell Sci 2004; 117:1259-68; PMID:14996945; http://dx.doi.org/10.1242/jcs.00997

18. Kissos WB, Shantil SJ, Pamori N, Schwartz MA. Rac recruits high-affinity integrin alphaVbeta3 to lamellipodia in endothelial cell migration. Nat Cell Biol 2001; 3:316-20; PMID:11231584; http://dx.doi.org/10.1038/35060120

19. Parker KK, Brock AL, Brangwynne C, Mannix RJ, Wang N, Ounui E, Geise NA, Adams JC, Whitesides GM, Ingber DE. Directional control of lamellipodia extension by constraining cell shape and orienting cell tractional forces. Faseb J 2002; 16:1195-204; PMID:12153987; http://dx.doi.org/10.1016/S0014-5793(03)00213-8

20. Baugher PJ, Krishnamoorthy L, Price JE, Dharmathri S, Fedorowicz SF. Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells. Breast Cancer Res Treat 2005; 7: R965-74; PMID:16280046; http://dx.doi.org/10.1007/s10549-005-8132-0

21. Vivanco I, Sawyer CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501; PMID:12094235; http://dx.doi.org/10.1038/nrc3939

This work was supported by: NIH grants 1P20MD002285 (VOM), G12MD007590 (VOM).
22. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploring the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4:988-1004; PMID:16431064; http://dx.doi.org/10.1038/nrd1902

23. Seger R, Krebs EG. The MAPK signaling cascade. Curr Opin Cell Biol 2002; 14:509-515; PMID:12006534

24. Zhao Z, Zhang W, Young D, Gleave MG, Rennie P. Activation of mitogen-activated protein kinase pathways mediated by oncogenic mutations of B-Raf. Cell 2004; 116:855-67; PMID:15035987; http://dx.doi.org/10.1016/S0092-8674(04)00215-6

25. McKeithen D, Graham T, Chung LW, Odero-Marah VA, Chunthapong J, Zou Z, Zhang W, Young D, Gleave MG, Rennie P. RAF. Cell 2004; 116:855-67; PMID:15035987; http://dx.doi.org/10.1016/S0092-8674(04)00215-6

26. Neal CL, Henderson V, Smith BN, McKeithen D, Odero-Marah VA, Khalkhali-Ellis Z, Chunthapong J, Han J, Luby-Phelps K, Das B, Shu X, Xia Y, Mosteller V. Snail-mediated regulation of cell migration. J Cell Sci 2004; 117:4619-28; PMID:15357163; http://dx.doi.org/10.1111/j.1471-2407.2004.01481.x

27. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995; 9:726-35; PMID:7601337

28. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298:1911-2; PMID:12371242; http://dx.doi.org/10.1126/science.1072682

29. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good YM, Jones CM, Marshall CJ, Springer CJ, Barford D. Mechanism of activation of the RAF-ERK signal transduction pathway by an oncogenic mutation of B-Raf. Cell 2004; 116:855-67; PMID:15035987; http://dx.doi.org/10.1152/jbc. M111.998940

30. Cantley LC. The phosphatidylinositol 3-kinase pathway. Cell 2002; 116:855-67; PMID:15035987; http://dx.doi.org/10.1016/S0092-8674(04)00215-6

31. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Nakamura K, Kakeya M, Abe S, Ogawa H, Obata T, et al. Activation of mitogen-activated protein kinase pathways in aggressive breast cancer cells. Cancer Biol Ther 2003; 2:988-403; PMID:14508113; http://dx.doi.org/10.1016/j.cubt.2004.06.003

32. Chubb L, Phillips K, Das B, Shu X, Xia Y, Mosteller V. Snail-mediated regulation of cell migration. J Cell Sci 2004; 117:4619-28; PMID:15357163; http://dx.doi.org/10.1111/j.1471-2407.2004.01481.x

33. Vial E, Sahai E, Marshall CJ. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 2003; 3:67-79; PMID:12902714; http://dx.doi.org/10.1016/S1535-5990(03)00162-4

34. Dokmanovic M, Hirsch DS, Shen Y, Wu WJ. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer. Mol Cancer Ther 2009; 8:1597-605; PMID:19590924; http://dx.doi.org/10.1158/1535-7155.MCT-09-0140

35. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Nakamura K, Kakeya M, Abe S, Ogawa H, Obata T, et al. Activation of mitogen-activated protein kinase pathways in aggressive breast cancer cells. Cancer Biol Ther 2003; 2:988-403; PMID:14508113; http://dx.doi.org/10.1016/j.cubt.2004.06.003

36. Shields MA, Krantz SB, Bentrem DJ, Dangi-Garimella M111.308940

37. McKeithen D, Graham T, Chung LW, Odero-Marah VA, Snail transcription factor regulates differential scattering and motility of pancreatic cancer cells by snail and Slug proteins. J Biol Chem 2012; 287:6218-29; PMID:22232555; http://dx.doi.org/10.1074/jbc. M111.308940

38. McKeithen D, Graham T, Chung LW, Odero-Marah VA. Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate 2010; 70:982-92; PMID:20166136

39. McKeithen D, Graham T, Chung LW, Odero-Marah VA, Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate 2010; 70:982-92; PMID:20166136

40. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Ratio-sensitive small molecule inhibitor. Proc Natl Acad Sci U S A 2007; 104:3919-24; http://dx.doi.org/10.1073/pnas.0608360104

41. Lu, H, et al. Fila-